Sumudu Rasangi Mallawaarachchi, G Paul Amminger, John Farhall, Luke K Bolt, Barnaby Nelson, Hok Pan Yuen, Patrick D McGorry, Connie Markulev, Miriam R Schäfer, Nilufar Mossaheb, Monika Schlögelhofer, Stefan Smesny, Ian B Hickie, Gregor Emanuel Berger, Eric Y H Chen, Lieuwe de Haan, Dorien H Nieman, Merete Nordentoft, Anita Riecher-Rössler, Swapna Verma, Andrew Thompson, Alison Ruth Yung, Kelly A Allott
Neurocognitive impairments are well established in both ultra-high risk (UHR) for psychosis and major depressive disorder (MDD). Despite this understanding, investigation of neurocognitive deficits in UHR individuals with MDD and its association with MDD within this population, has been scarce. Hence, this study aimed to examine any differences in neurocognition at baseline between those with MDD at baseline and those with no history of MDD, as well as determine whether neurocognitive variables are significantly associated with meeting criteria for MDD at follow-up, while controlling for relevant clinical variables, within a UHR cohort...
March 11, 2020: Schizophrenia Research